RBC Capital Downgrades Mylan to Sector Perform (MYL)
Mylan (NYSE:MYL) opened at 46.49 on Friday. Mylan has a 52 week low of $34.46 and a 52 week high of $57.52. The stock’s 50-day moving average is $50.79 and its 200-day moving average is $49.57. The company has a market cap of $17.375 billion and a P/E ratio of 29.93.
Mylan (NYSE:MYL) last announced its earnings results on Thursday, August 7th. The company reported $0.69 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.73 by $0.04. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the prior year, the company posted $0.68 earnings per share. The company’s quarterly revenue was up 7.9% on a year-over-year basis. Analysts expect that Mylan will post $3.37 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup Inc. downgraded shares of Mylan from a “buy” rating to a “neutral” rating in a research note on Friday, July 25th. They now have a $57.00 price target on the stock, down previously from $61.00. Separately, analysts at Deutsche Bank initiated coverage on shares of Mylan in a research note on Tuesday, July 22nd. They set a “buy” rating and a $67.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $54.11.
Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.
Receive News & Ratings for Mylan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.